ghk-cu acetat topical Cream Compounded GHK-Cu Topical Cream —

"As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine

& Tchekhovskoi, D

Mycobacterium marinum engineered to fluoresce when encountering a Pi concentration of 1500 lipid species and allowing Mtb to overcome Pi limitation

In the liver, BPC 157 reduced congestion and severe sinusoid enlargement

10.3317/jraas.2007.016